Misonix, Inc. to Present at the 29th Annual Piper Jaffray Healthcare Conference
November 24 2017 - 12:30PM
Misonix, Inc. (NASDAQ:MSON), a provider of
minimally invasive therapeutic ultrasonic medical devices that
enhance clinical outcomes, announced today that Stavros
Vizirgianakis, President and Chief Executive Officer, and Joe
Dwyer, Chief Financial Officer, will present at the
29th Annual Piper Jaffray Healthcare Conference on Wednesday,
November 29, 2017 at 3:30 pm ET. The conference will be held at The
Lotte New York Palace in New York City.
About MisonixMisonix, Inc. designs, develops,
manufactures and markets therapeutic ultrasonic medical devices.
Misonix's therapeutic ultrasonic platform is the basis for several
innovative medical technologies. Addressing a combined market
estimated to be in excess of $1.5 billion annually; Misonix's
proprietary ultrasonic medical devices are used in spine surgery,
neurosurgery, orthopedic surgery, wound debridement, cosmetic
surgery, laparoscopic surgery, and other surgical and medical
applications. Additional information is available on the
Company's Web site at www.misonix.com.
Safe Harbor StatementWith the exception
of historical information contained in this press release and in
the conference presentation referenced above, content herein may
contain "forward looking statements" that are made pursuant to the
Safe Harbor Provisions of the Private Securities Litigation Reform
Act of 1995. These statements are based on management's current
expectations and are subject to uncertainty and changes in
circumstances. Investors are cautioned that forward-looking
statements involve risks and uncertainties that could cause actual
results to differ materially from the statements made. These
factors include general economic conditions, delays and risks
associated with the performance of contracts, risks associated with
international sales and currency fluctuations, uncertainties as a
result of research and development, acceptable results from
clinical studies, including publication of results and
patient/procedure data with varying levels of statistical
relevancy, risks involved in introducing and marketing new
products, potential acquisitions, consumer and industry acceptance,
litigation and/or court proceedings, including the timing and
monetary requirements of such activities, the timing of finding
strategic partners and implementing such relationships, regulatory
risks including approval of pending and/or contemplated 510(k)
filings, the ability to achieve and maintain profitability in the
Company's business lines, the impact of the
pending investigation by the Department of Justice and Securities
Exchange Commission, and other factors discussed
in the Company's Annual Report on Form 10-K, subsequent Quarterly
Reports on Form 10-Q and Current Reports on Form 8-K. The Company
disclaims any obligation to update its forward-looking
relationships.
Corporate Contact
Misonix
Contact:
Joe Dwyer
631-694-9555
invest@misonix.com
Investor ContactJoe DiazLytham
Partners602-889-9700info@misonix.com
Misonix (NASDAQ:MSON)
Historical Stock Chart
From Aug 2024 to Sep 2024
Misonix (NASDAQ:MSON)
Historical Stock Chart
From Sep 2023 to Sep 2024